Glucose-induced glucagon-like Peptide 1 secretion is deficient in patients with non-alcoholic fatty liver disease.
about
Multiple Factors Related to the Secretion of Glucagon-Like Peptide-1Basal insulin combined incretin mimetic therapy with glucagon-like protein 1 receptor agonists as an upcoming option in the treatment of type 2 diabetes: a practical guide to decision makingSleep Disruption and Daytime Sleepiness Correlating with Disease Severity and Insulin Resistance in Non-Alcoholic Fatty Liver Disease: A Comparison with Healthy ControlsMolecular mechanisms and new treatment strategies for non-alcoholic steatohepatitis (NASH)Potential roles of glucagon-like peptide-1-based therapies in treating non-alcoholic fatty liver disease.The gut microbiota of nonalcoholic fatty liver disease: current methods and their interpretationHigher BNP levels within physiological range correlate with beneficial nonfasting lipid profiles in the elderly: a cross-sectional studyPharmacokinetics in patients with chronic liver disease and hepatic safety of incretin-based therapies for the management of type 2 diabetes mellitus.Diagnosis and management of cardiovascular risk in nonalcoholic fatty liver disease.Bile acid supplementation improves established liver steatosis in obese mice independently of glucagon-like peptide-1 secretion.Incretin-based therapies for the treatment of non-alcoholic fatty liver disease: A systematic review and meta-analysis.Diabetic and nondiabetic patients with nonalcoholic fatty liver disease have an impaired incretin effect and fasting hyperglucagonaemia.A computer model simulating human glucose absorption and metabolism in health and metabolic disease states.Regulation of glucose metabolism in non-diabetic, metabolically-obese normal-weight Asians.Increased prevalence and risk of non-alcoholic fatty liver disease in overweight and obese patients with Type 2 diabetes in South China.Future Perspectives on GLP-1 Receptor Agonists and GLP-1/glucagon Receptor Co-agonists in the Treatment of NAFLD
P2860
Q26781127-26B52493-747F-4811-B26E-62F32A147888Q26992979-FABBB32C-5706-4DFA-A490-6546889267CCQ28551009-A8500D43-8C2A-4841-A579-97B13631D58AQ33755566-F9F5B7D0-2515-42E0-90CA-D3463E1F035AQ33970970-A196B827-884C-4624-891C-651462B80C94Q35661635-4288FB5F-8492-496A-9993-016634B36880Q36428904-56C420BD-2575-4360-96C2-0D702215EF28Q38236774-C5D95669-C3E2-4E2B-9A55-DFA4042A5DCDQ38261236-D228137F-ACC4-44E7-A589-A34EA8CDDAF1Q38307168-E363B2E8-19F1-4BCD-B7C8-AD271808A238Q38537853-D8F5594E-8BAC-49A5-BCDF-E78A5A9CA1ECQ40147836-882CB065-1DCB-4D34-9611-2285A18EFF12Q42707414-5B6A0778-4942-4E60-9E71-CDB9421E584EQ49917632-DF841335-5998-4B22-A5B9-F7A03F1F6E78Q50884189-2EE9D383-D389-4DBF-A282-00BAB768DFE8Q59136513-47A023C5-B949-4FA1-8DC3-CE12EF799FF4
P2860
Glucose-induced glucagon-like Peptide 1 secretion is deficient in patients with non-alcoholic fatty liver disease.
description
2014 nî lūn-bûn
@nan
2014 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Glucose-induced glucagon-like ...... alcoholic fatty liver disease.
@ast
Glucose-induced glucagon-like ...... alcoholic fatty liver disease.
@en
type
label
Glucose-induced glucagon-like ...... alcoholic fatty liver disease.
@ast
Glucose-induced glucagon-like ...... alcoholic fatty liver disease.
@en
prefLabel
Glucose-induced glucagon-like ...... alcoholic fatty liver disease.
@ast
Glucose-induced glucagon-like ...... alcoholic fatty liver disease.
@en
P2093
P2860
P50
P1433
P1476
Glucose-induced glucagon-like ...... alcoholic fatty liver disease.
@en
P2093
Anne C Meyer-Gerspach
Christoph Beglinger
Lea S Blaser
P2860
P304
P356
10.1371/JOURNAL.PONE.0087488
P407
P577
2014-01-29T00:00:00Z